Clinical Trial Detail

NCT ID NCT01306045
Title Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

lung small cell carcinoma

thymus cancer

Therapies

Erlotinib

Lapatinib

MK2206

Sunitinib

Selumetinib

Age Groups: adult senior

Additional content available in CKB BOOST